Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is

Tools
- Tools
+ Tools

Juan, O., Yousaf, N., Popat, S. (2017) First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is. CLINICAL ONCOLOGY, 29 (1). E1-E4. ISSN 0936-6555

Full text not available from this repository.

Item Type: Editorial
Authors (ICR Faculty only): Popat, Sanjay
All Authors: Juan, O., Yousaf, N., Popat, S.
Additional Information: ISI Document Delivery No.: EI6ZZ Times Cited: 0 Cited Reference Count: 31 Juan, O. Yousaf, N. Popat, S. NHS O. Juan acknowledges the Spanish Society of Medical Oncology (SEOM) and the CRIS Cancer foundation to support the collaboration with the Royal Marsden Hospital. S. Popat and N. Yousaf acknowledge NHS funding to the Royal Marsden Hospital NIHR-Biomedical Research Centre. 0 ELSEVIER SCIENCE LONDON LONDON CLIN ONCOL-UK
Uncontrolled Keywords: RANDOMIZED PHASE-3 TRIAL OPEN-LABEL NETWORK METAANALYSIS PROGRESSION-FREE CHEMOTHERAPY MUTATIONS ERLOTINIB ADENOCARCINOMA AFATINIB GEFITINIB
Research teams: Clinical Units > Lung Unit
ICR divisions > Clinical Studies > Thoracic Oncology
Depositing User: Barry Jenkins
Date Deposited: 01 Mar 2017 16:34
Last Modified: 01 Mar 2017 16:34
URI: http://publications.icr.ac.uk/id/eprint/15695

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust